SEARCH

SEARCH BY CITATION

Fig S1. Evolution of the modified Health Assessment Questionnaire for Scleroderma at each study visit (month 0, 1, 3, 6 and 12). (a) Patients treated with imatinib mesylate; (b) patients treated with placebo.

Fig S2. Evolution of the patients’ weight at each study visit (month 0, 1, 3, 6 and 12). (a) Patients treated with imatinib mesylate; (b) patients treated with placebo.

Appendix S1. (a) Sensitivity analysis. (b) Summary of investigations after unblinding concerning placebo patients with plasmatic imatinib positive dosage.

FilenameFormatSizeDescription
BJD_11186_sm_FigsS1-S2-AppendixS1.doc93KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.